Related Experiment Video

Updated: Jul 4, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

Angelo J Casa1, Robert K Dearth, Beate C Litzenburger

  • 1Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|May 30, 2008
PubMed

Insights

The insulin-like growth factor-I receptor (IGF-IR) pathway drives cancer growth and therapy resistance. Inhibiting IGF-IR alongside standard treatments may improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • Insulin-like growth factor (IGF) ligands activate the type I insulin-like growth factor receptor (IGF-IR), promoting cellular proliferation and survival.
  • The IGF signaling system is frequently dysregulated in various cancers, including breast, prostate, and lung cancer.
  • IGF-IR plays crucial roles in tumor development and critically influences patient response to cancer therapies.

Purpose of the Study:

  • To review the role of the IGF-IR pathway in mediating resistance to cancer therapies.
  • To explore therapeutic strategies targeting the IGF-IR pathway.
  • To evaluate the potential of inhibiting IGF signaling to enhance cancer treatment efficacy.

Main Methods:

  • Literature review of studies investigating the IGF-IR pathway in cancer.
  • Analysis of IGF-IR's role in resistance to cytotoxic therapies (radiation, chemotherapy).
  • Examination of IGF-IR's involvement in resistance to targeted therapies (tamoxifen, trastuzumab).

Main Results:

  • The IGF-IR pathway contributes to resistance against various cancer treatments.
  • IGF-IR mediates resistance to both conventional cytotoxic agents and targeted therapies.
  • Targeting IGF-IR presents a promising strategy to overcome treatment resistance.

Conclusions:

  • Inhibition of IGF signaling, combined with standard therapies, holds potential to improve cancer cell response.
  • Targeting the IGF-IR pathway could enhance the effectiveness of multiple cancer treatment modalities.
  • Further research into IGF-IR inhibition strategies is warranted for improved cancer therapeutics.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...